RELMADA THERAPEUTICS, INC. (RLMD) Stock Analysis
RELMADA THERAPEUTICS, INC.
▾ What's in the 37/100 risk score? (higher = riskier)
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). See the Financial Health section for the full balance-sheet read.
How to read RLMD (pre-profit growth)
This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.
-
1
Reverse-DCF — the growth the price demands ↓
It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
-
2
Cash runway ↓
Can it reach profitability before it has to raise money and dilute shareholders?
-
3
Interactive calculator ↓
Set your own growth + margin assumptions and see what the business would be worth if you are right.
Standard DCF doesn't fit RLMD well — but that's expected for this kind of business. The Rule of 40 (Pre-Profit Growth) Lens below uses the metrics actually used by analysts who value pharmaceuticals. Reverse DCF + Football Field also work as cross-checks.
Riskier than 51% of the stocks we cover
A model trained on every US filing since 2012 — including the 823 companies that went bankrupt or stopped trading under a dollar — ranks each covered stock by its chance of failing in the next year. This is a position among peers, not a prediction about this company alone. Below is what happened to stocks that sat in the same position in past years.
▾ Every band, and what happened to the stocks in it
| Rank band | went bankrupt within 12 months | fell 80% or more (or failed) within 12 months | fell 50% or more (or failed) within 6 months |
|---|---|---|---|
| All covered stocks (average) | 0.59% | 4.21% | 8.51% |
| Healthcare (sector average) | 0.94% | 9.47% | 17.69% |
| riskiest 1% | 16.4% of 1,749 | 33.0% of 1,998 | 45.5% of 2,239 |
| next 2% (97-99) | 5.9% of 3,360 | 24.9% of 3,985 | 38.2% of 4,461 |
| next 2% (95-97) | 3.4% of 3,409 | 21.2% of 3,984 | 33.8% of 4,462 |
| next 5% (90-95) | 1.6% of 8,443 | 15.1% of 9,965 | 27.3% of 11,155 |
| next 15% (75-90) | 0.8% of 25,328 | 8.5% of 29,884 | 17.8% of 33,459 |
| next 25% (50-75) ← this stock | 0.2% of 36,310 | 2.7% of 49,810 | 6.2% of 55,771 |
| safest half | <0.1% of 92,256 | 0.5% of 99,617 | 2.1% of 111,538 |
Counts are stock-quarters 2012–2025, scored each year by a model that had not seen that year. The rank is recomputed from each company's latest filing (this one: 2026-05-13); table generated 2026-09-17. Calibrated one-year odds for this stock alone: bankruptcy 0.1%, 80%+ fall 9.0%, 50%+ fall in six months 21.5% — treat these as rougher than the band counts; the model overstates the middle of the range.
What this is not. It is not a trade. We tested shorting these names and buying puts on them at real option prices (2010–2025): every version lost money, because the market already prices the distress and the survivors squeeze. A high rank is a reason to read the filings and to size a position for the chance of a total loss — not a reason to bet against the company. A low rank says the balance sheet and the market are calm; it says nothing about whether the price is sensible.
How to read a company this small
This is a clinical-stage biotech with little or no revenue. Standard DCF requires future cash flows to discount — there's nothing to discount yet. The value is entirely in the drug pipeline and the probability that it works.
- Drug pipeline — phase of each candidate (Phase I → II → III → FDA approval); each phase has historical success probabilities
- Total Addressable Market (TAM) of the lead indication — bigger market = bigger payoff if approved
- Cash runway — months of cash left at current burn rate before they need to raise more (and dilute shareholders)
- Strategic partnerships — Big Pharma collaborations validate the science and bring milestone payments
- Patent / exclusivity timeline — how long until generics if approved
- Insider holdings + management track record — biotech execs with prior wins are a real signal
P/E, P/B, EV/Sales, ROE — meaningless when there's no revenue or earnings. DCF outputs are nonsense.
ClinicalTrials.gov for trial status. The 10-K's "Pipeline" section. Recent press releases on Phase II/III readouts. Conferences like JPM Healthcare or ASCO.
Classified as Clinical-Stage Biotech (confidence 85%). Disagree? An admin can override via the post edit screen.
How does RLMD stack up against its closest peers?
We take the 8 same-industry companies most similar to RLMD (similar size) and check what investors are paying for each dollar of their revenue (or profits). If RLMD is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, FCF yield (in the table) is usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.
▾ What's "EV / Sales" in plain English?
EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.
EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).
p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.
Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 same-industry peers; implausible multiples excluded.
⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.
▾ View peer list (8)
| Ticker | Company | Industry | Mcap | EV/Sales | EV/GP | EV/EBIT | FCF Yield |
|---|---|---|---|---|---|---|---|
| TLSA | Tiziana Life Sciences Ltd | Pharmaceuticals | $170M | — | — | — | — |
| TNXP | Tonix Pharmaceuticals Holding Corp | Pharmaceuticals | $197M | 15.0x | — | — | 0.6% |
| UNCY | Unicycive Therapeutics, Inc. | Pharmaceuticals | $197M | — | — | — | — |
| SGMT | Sagimet Biosciences Inc. | Pharmaceuticals | $224M | — | — | — | — |
| WHWK | Whitehawk Therapeutics, Inc. | Pharmaceuticals | $233M | 32.7x | — | — | 0.1% |
| TRIB | TRINITY BIOTECH PLC | Pharmaceuticals | $263M | — | 12.3x | — | — |
| TRDA | Entrada Therapeutics, Inc. | Pharmaceuticals | $274M | 10.8x | — | — | 0.9% |
| TTRX | Turn Therapeutics Inc. | Pharmaceuticals | $284M | — | — | — | — |
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.
▾ The checks — what passed, what didn't (and what we couldn't measure)
-
✗ Positive net incomeNet income -$57.4M in FY2025.Why this matters: Does the company actually earn a profit? Sustained losses eventually force it to raise money — diluting you — or take on debt.
-
✗ Positive operating cash flowOperating cash flow -$45.8M (was -$51.8M the prior year).Why this matters: Profit can be an accounting figure; cash from running the business is harder to fake. Negative operating cash flow means the core business consumes cash and must be funded externally.
-
✓ Cash flow backs up reported profitOperating cash flow -$45.8M vs net income -$57.4M.
-
✓ Return on assets improvingReturn on assets -61.0% vs -174.6% a year ago.
-
✓ Debt load (vs assets)The filing reports no interest-bearing debt in either year (total assets $94.0M).
-
✓ Short-term liquidity (current ratio)Current ratio 14.62x vs 4.45x a year ago.
-
✗ Share count (dilution)Share count rose 30.9% (30.2M → 39.5M year-over-year).Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
-
· Pricing power (gross margin) (n/a — data not reported; not scored)
-
· Sales per asset (asset turnover) (n/a — data not reported; not scored)
Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.
Plain English: the company holds about $3M in cash and is burning roughly $46M/year in operations. At that pace, the cash lasts 1 mo before it must raise capital (diluting shareholders), take on debt, or cut spending.
Assumes constant burn and ignores financing/asset sales. For pre-profit biotech and growth companies, this matters more than a DCF — a great drug pipeline is worthless if they run out of money before approval.
A standard discounted cash flowDCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
Full explanation → (DCF) valuation is not meaningful for RELMADA THERAPEUTICS, INC. because the company has negative net income and operating cash flow, indicating it is not currently generating profits or positive cash from operations. Valuing RLMD would require projecting future drug development success and market penetration, which are highly speculative. Investors are likely betting on the potential success of its drug pipeline. The primary quantifiable risk is the continued negative operating cash flow, which implies ongoing cash burn.
As of 3 months ago
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What's free cash flow / what do these mean?
Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.
Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.
Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.
Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
- Announcement of Phase 2 or Phase 3 clinical trial results
- Submission of a New Drug Application (NDA)
- Securing new financing rounds
The trend, in plain numbers (FY2024 → FY2025, latest reported)
Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.
- Free cash flow is negative at -$59.7M — the cash burn narrowed vs last year.
- Still unprofitable at -$57.4M — loss narrowing.
Nothing was clearly worsening year-over-year.
Management & Leadership
J. Kevin Adams serves as the Chief Executive Officer of RELMADA THERAPEUTICS, INC., a role he has held for several years, guiding the company's strategic direction in pharmaceutical development. He is also the Chairman of the Board.
What They Make
RELMADA THERAPEUTICS, INC. is a pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders. Its primary customers are patients suffering from these conditions, with products distributed through healthcare providers.
End Markets
Revenue Drivers
Why Is It Priced Like This?
Why Customers Pay
What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.
The market is pricing RLMD based on the potential future value of its drug pipeline, rather than current cash flows, as evidenced by its negative net income and operating cash flow. The market may be assigning value to the potential for a successful drug approval, which is not in the model. Investors are likely focused on clinical trial progress and regulatory milestones, which could dramatically alter the company's financial trajectory.
Business Model & Valuation
How They Make Money
The company funds itself primarily through equity raises, given its negative operating cash flow and lack of dividend payments or buybacks.
Growth / Revenue DCF
Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.
Show advanced inputs
| Revenue Growth | 15.0% |
What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
Moat Signals
Net income has been negative for the latest period and 0/5 years, and operating cash flow has been negative for the latest period and 0/5 years.
Geography & Markets
RELMADA THERAPEUTICS, INC. is headquartered in the United States. While specific geographic revenue mix is not available, its drug development efforts target global markets.
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)51.3NeutralMomentum is balanced — neither overbought nor oversold.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BearishLine below signalThe fast trend is below the slow trend — short-term momentum is currently downward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
QUALITY
Data Quality & Risk Flags (4 notes — click to expand/collapse)
Guardrail Notes (4)
- FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
- INVARIANT: weighted IV is non-positive. Model may not be appropriate.
- Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
- Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
FINANCIALS
Financial Statements (5-year tables — click to expand)
From RELMADA THERAPEUTICS, INC.'s SEC filings (EDGAR).
Income (5yr)
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | — | -57.4M | $-1.45 |
| 2024 | — | -80.0M | $-2.65 |
| 2023 | — | -98.8M | $-3.28 |
| 2022 | — | -157.0M | $-5.30 |
| 2021 | — | -125.8M | $-7.16 |
Cash Flow (5yr)
Capital expenditure isn't tagged in this filer's machine-readable data (the CapEx column shows "—"). The free-cash-flow column is therefore operating cash flow less stock-based compensation only — an upper bound on true owner earnings, not the real figure. Companies that report capex under a custom label (some large IFRS filers do) look better here than they are.
| Year | Operating CF | CapEx | − SBC & adj. | Free Cash Flow |
|---|---|---|---|---|
| 2025 | -45.8M | — | 13.9M | -59.7M |
| 2024 | -51.8M | — | 30.2M | -81.9M |
| 2023 | -51.7M | — | 43.8M | -95.5M |
| 2022 | -103.8M | — | 44.2M | -148.0M |
| 2021 | -91.9M | — | 40.5M | -132.4M |
How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: -45.8M − — − 13.9M (SBC & adj.) = -59.7M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.
Balance Sheet
| Total Assets | 94.0M |
| Total Liabilities | 7.5M |
| Equity | 86.5M |
Similar companies worth a look
Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.